AstraZeneca (AZN) said Monday that a final overall survival analysis of its phase 3 study for patients with 1st line locally advanced or metastatic epidermal growth factor receptor-mutated, or EGFRm, non-small cell lung cancer showed improvement in key secondary endpoints.
The FLAURA2 phase 3 study evaluated Tagrisso in combination with pemetrexed and platinum-based chemotherapy in patients with EGFRm lung cancer.
"Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer," the company said.
The latest analysis is in line with the interim overall survival report and builds on the previously presented primary endpoint data, which demonstrated the longest-reported median progression-free survival in this setting, AstraZeneca said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。